Michael Best & Friedrich LLP is pleased to announce the agenda for an educational and networking event titled Best Summit for Life Sciences, University and Higher Education – How Does the Legal Landscape Affect Your IP Portfolio?
The day will begin with a welcome by attorney and Chair of Michael Best’s Life Sciences and Chemical practice, Lisa L. Mueller. The summit will then break out into a series of four sessions, each with three workshop options, conducted throughout the remainder of the day. These workshops will be led by Michael Best attorneys and several guest panelists from the Midwest, across the United States and throughout the world. Topics will include patents and patent litigation, valuation, venture capital and licensing, trade secrets, FDA and regulatory matters and immigration, and one workshop will feature a mock inter partes review oral hearing. All workshop topics and details are noted below.
8:30-9:00 a.m. Registration and Continental Breakfast
9:00-9:30 a.m. Opening Remarks
Lisa L. Mueller, Michael Best
Attorney & Chair of Michael Best's Life Sciences and Chemical Practice
9:30-10:30 a.m. IP and Strategic Alliances
Presenter: Jeffrey D. Peterson
This workshop will discuss how two technology parties can work together, through legal structures including joint development structures, joint ventures or other partnering structures. Jeff will cover how ownership and licensing of jointly created intellectual property can be structured, and the pros and cons of such structures.
10:45-11:45 a.m. Patent Protection and Enforcement for Life Science inventions in the Middle East and North Africa
Moderated by: Lisa L. Mueller
Panelists include: Sara Holder, Rouse and Sandra Clelland, Von Siedels/Rouse
Countries in the Middle East and Africa have taken significant steps to establish diversified knowledge-based economies. Recently, these countries have seen tremendous growth and a demand for life science technologies, particularly with respect to pharmaceuticals, biopharmaceuticals and medical devices. This workshop will explore the requirements for protecting and enforcing life science inventions in countries such as Saudi Arabia, GCC, UAE, Egypt, South Africa, Algeria, Tunisia and more. Panelists will provide tips and suggestions to maximize patent protection in these countries, and will also address the evolution of enforcement regimes in these jurisdictions and how to best prepare for litigation should this become necessary.
11:45 a.m.-12:15 p.m. Lunch
1:30-2:30 p.m. Presenting Oral Arguments at the PTAB
Presenter: Andrew T. Dufresne, Ph.D., Gilberto E. Espinoza
Mock panel administrative patent judges include: Marshall J. Schmitt, Michael Best; John Haugen, Takeda Pharmaceuticals; and Elese Hanson, Sagent Pharmaceuticals.
This workshop will conduct a mock inter partes review oral argument before a mock panel of administrative patent judges. The presentation will include a brief description of the case, the mock oral argument and a discussion regarding the practice and impact of oral arguments in America Invents Act (AIA) trials.
1:30-2:30 p.m. Patent Term Extension, Supplementary Patent Certificates and Other Ways to Extend a Patent Term
Moderated by: Lisa L. Mueller, Michael Best
Panelists include: Alejandra Luna, Olivares; Daphne Lainson, Smart & Biggar/Fetherstonhaugh; Maya Hirose, Takeda Pharmaceuticals U.S.A., Inc.; and Nina White, Boult Wade Tennant
As the area of patent life cycles continues to become more complex, it is extremely important for pharmaceutical companies to capitalize on their research and development by extending patent terms in all available jurisdictions by utilizing patent term extensions, supplementary protection certificates and other legal and technical mechanisms. This workshop will explore such routes and strategies and will ensure you are in the best position possible to extend your patent life cycles in key global jurisdictions such as Canada, Mexico, Europe and Japan.
2:30-3:30 p.m. 2017 FDA Predictions
Presenter: Seth E. Mailhot
This workshop will address significant challenges facing the agency in 2017. Pending rule making, ongoing major agency litigation and planned operations and policy changes within the FDA will be discussed. In addition, the workshop will also address the upcoming change in administration and how it is expected to influence the FDA.
3:30 p.m. Adjourn